- Deutsche Bank downgraded Genmab ( GMAB ) to hold from buy saying that it is does not expect upcoming data on candidates to be presented at two upcoming conferences to lead to upside.
- The firm has a price target of DKK 3100 (~3% upside based on Friday's close on the Copenhagen Stock Exchange).
- Analyst Emmanuel Papadakis said he does not anticipate data that will be presented at an European Society for Medical Oncology Immuno-Oncology Congress in December on GEN1042, which targets to CD40 and 4-1BB, "to surprise on the upside."
- He also expressed concerns on GEN3014 (HexaBody-CD38), as " the early hexabody evidence is best described as inconclusive." Data from a phase 1/2 trial will be presented at the American Society of Hematology Annual Meeting, also next month,
- Check out why Seeking Alpha contributor Avisol Capital Partners recently rated Genmab ( GMAB ) a hold.
For further details see:
Genmab downgraded to hold at Deutsche Bank on candidate data at upcoming conferences